Faricimab for Polypoidal Choroidal Vasculopathy: 48-Week Results from the Phase 3b/4 SALWEEN Trial

Further Publications

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial

JAMA Ophthalmol

Lee WK, Wong TY, Chen SJ, Sun X, Cheung CMG, Silva R, Ricci F, Zhang X, Machewitz T, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Iida T, PULSAR Study Investigators

doi: 10.1001/jamaophthalmol.2025.5098

Macular Diseases

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Ophthalmology

Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators

doi: 10.1016/j.ophtha.2025.10.028

Further Publications

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials

Ophthalmology

Briceño CA, Idowu OO, Khong JJ, Kuenzel T, Tran AQ, Brittain C, Azumi A, Brockwell L, Ghadiri N, Coronel M, Ruf T, Li D, Salvi M, Garrido-Hermosilla AM, Barteselli G, Ortiz-Perez S, of the SatraGO-1 and SatraGO-2 investigators

doi: 10.1016/j.ophtha.2026.08.039

Macular DiseasesRetinal Diseases

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Ophthalmology

Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG, GATHER2 trial investigators

doi: 10.1016/j.ophtha.2025.12.011

Macular DiseasesRetinal Diseases

Prevalence of Polypoidal Choroidal Vasculopathy Beyond Recalcitrant Macular Neovasculopathies in a European AMD Cohort and Therapeutic Response to Brolucizumab

J Clin Med

Spindler J, Pfister IB, Weinberger A, Garweg JG

doi: 10.3390/jcm15041492

Retinal Diseases

Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial

Lancet Neurol

Préterre C, Gaultier A, Obadia M, Vignal C, Mourand I, Plat J, Sablot D, Gaudron M, Rodier G, Godeneche G, Urbanczyk C, Marc G, Massardier E, Adam S, Boulanger M, Marcel S, Mechtouff L, Ronzière T, Calvière L, Godard-Ducceschi S, Barbin L, Lebranchu P, Guillon B, THEIA collaborators

doi: 10.1016/S1474-4422(25)00308-4

Retinal Diseases

Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 Trials

Ophthalmol Retina

Sharma S, Dhoot DS, Grewal DS, Jung E, Silva FQ, Du W, Moini H, Boyer DS

doi: 10.1016/j.oret.2026.04.027

Glaucoma and Ocular PressureFurther Publications

Vision-related quality of life following trabeculectomy versus Baerveldt glaucoma implant: Five-year results from a randomized clinical trial

Acta Ophthalmol

Popescu-Giovanitsas I, Woudstra-de Jong JE, Vingerling JR, de Waard PWT, Bonnemaijer PWM

doi: 10.1111/aos.70176

Dry Eye Disease

Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal Studies COMET-2 and COMET-3

Ophthalmology

Pattar GR, Wirta D, Jerkins G, Paauw J, McLaurin EB, Liu A, Evans DG, Kenyon K, Cline N, Gupta PK, Meng I, Senchyna M, COMET-2 and COMET-3 study groups

doi: 10.1016/j.ophtha.2025.09.018

Related content

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Prevalence of Polypoidal Choroidal Vasculopathy Beyond Recalcitrant Macular Neovasculopathies in a European AMD Cohort and Therapeutic Response to Brolucizumab

Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial

Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 Trials

Vision-related quality of life following trabeculectomy versus Baerveldt glaucoma implant: Five-year results from a randomized clinical trial

Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal Studies COMET-2 and COMET-3